The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Oxford Myeloma Workshop 2025 | The 5th Oxford Myeloma Meeting: key topic areas covered at the event
In this video, Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, expresses his excitement about the 5th Oxford Myeloma Meeting and outlines the key topic areas discussed at the event. Dr Ramasamy highlights that the meeting is a valuable opportunity for attendees to share insights and contribute to the efforts to improve the outcomes of patients with multiple myeloma (MM). This interview took place at the 5th Oxford Myeloma Workshop in Oxford, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
We’re excited about the 5th Oxford Myeloma Workshop. We have some great speakers tackling kind of four key areas. One is around clinical challenges currently existing still for myeloma patients. Looking at how the current research can impact on clinical practice is another topic that we’re looking at. The third is we continue to discover new novel mechanisms of treating myeloma...
We’re excited about the 5th Oxford Myeloma Workshop. We have some great speakers tackling kind of four key areas. One is around clinical challenges currently existing still for myeloma patients. Looking at how the current research can impact on clinical practice is another topic that we’re looking at. The third is we continue to discover new novel mechanisms of treating myeloma. So we have a session focused on it. And we’re also focused on the novel methodologies that can impact on myeloma care, both on the bench research as well as translational research. So we’ve got a great set of speakers and hopefully we’ll have a good discussion and debate to try and see what we can all collectively take back home to continue to make a difference to myeloma patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
GSK: Consultancy, Research Funding, Speakers Bureau; Takeda: Consultancy, Speakers Bureau; Sanofi: Consultancy, Research Funding, Speakers Bureau; Bristol Myers Squibb: Consultancy, Research Funding, Speakers Bureau; Amgen: Consultancy, Research Funding, Speakers Bureau; Adaptive Biotech: Consultancy, Speakers Bureau; Johnson and Johnson: Consultancy, Speakers Bureau; Menarini Stemline: Consultancy, Speakers Bureau; Pfizer: Consultancy, Speakers Bureau; Recordati rare Disease: Consultancy, Speakers Bureau.
